Technology


The MethDet® technology provides several benefits that other competing technologies do not deliver. These include the following:
  • Whole genome analysis in in ultra-small sample samples (less than 1 ng or less than 200 cells); 
  • Whole genome analysis in difficult samples including cell-free circulating (CFC) DNA from blood, tissue biopsies (fresh, fresh-frozen or FFPE), laser-captured areas of tissue sections (LCM), and circulating tumor cells (CTC) from blood;
  • Whole genome analysis in  cell-free circulating DNA from blood and other biological fluids for continuous testing on a genome-wide basis.
The MethDet® technology has an unmatched power to 
  • Determine DNA methylation in every fragment of the whole genome when the sample is too small for other technologies;
  • Define DNA methylation in every fragment of the whole genome regardless of the sample's nature - biopsies, laser-captured areas of tissue sections, circulating tumor cells, and cytological slides using fresh, fresh-frozen or fixed samples;
  • Assess cell-free circulating DNA from blood or any other biological fluid for continuous testing on a genome-wide basis;
  • Analyze DNA methylation in every fragment of the whole genome of any organism when a target microarray is available.
© Copyright 2017. US Biomarkers Inc. All Rights Reserved.